PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9542519

Endothelin-1 and tumour development.

E H Asham·M Loizidou·I Taylor
View original source ↗Export metadata ↓

Abstract

There has been a growing conviction amongst oncologists that cancer is a disease characterized by changes in specific molecules. These changes include alteration in the structure, regulation or quantity of growth factors and their receptors, signal transducers and the proteins encoded by dominant or suppressor/recessive oncogenes. The role of endothelin (vasoactive peptide) in tumour cell signal transduction and mitogenesis and induction of endothelial cell growth and angiogenesis in tumour growth is discussed in this article.

Explore related subjects

Endothelin-1HumansMitogensNeoplasmsNeovascularization, PathologicReceptors, EndothelinSignal TransductionJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E H Asham, M Loizidou, I Taylor. 1998. Endothelin-1 and tumour development.. https://doi.org/10.1016/s0748-7983(98)80128-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma.

BACKGROUND: Endothelin-1 (ET-1), a potent vasoconstrictor, is difficult to measure because of its instability and its binding to receptors and plasma proteins. We report a rapid, robust way to indirectly quantify ET-1 release by measuring the C-terminal ET-1 precursor fragment (CT-proET-1) without an extraction step. METHODS: In plasma samples from healthy individuals, patients with congestive heart failure (CHF), and patients with sepsis, we measured CT-proET-1 with a sandwich immunoluminometric assay that uses 2 polyclonal antibodies to amino acids 168-212 of pre-proET-1. We also correlated CT-proET-1 concentrations with bigET-1 measurements. RESULTS: The assay yielded results within 3 h and showed linear dilution with an analytical detection limit of 0.4 pmol/L and an interlaboratory CV <10% for values >10 pmol/L. Ex vivo CT-proET-1 was stable (<10% loss of immunoreactivity) in EDTA-, heparin-, and citrate-plasma for at least 4 h at room temperature, 6 h at 4 degrees C, and in EDTA-plasma for at least 6 months at -20 degrees C. CT-proET-1 values followed a gaussian distribution in healthy individuals (mean, 44.3 pmol/L; range, 10.5-77.4 pmol/L) without significant differences between males and females. The correlation coefficient for CT-proET-1 vs age was 0.25 (P <0.0001). CT-proET1 was significantly (P <0.0001) increased in patients with CHF (median, 104 pmol/L; range, 50.8-315 pmol/L) and patients with sepsis (median, 189 pmol/L; range, 34.6-855 pmol/L). The correlation between CT-proET-1 and bigET-1 for 43 samples was 0.80 (P <0.0001). CONCLUSIONS: CT-proET-1 measurement is a rapid and easy method for indirectly assessing the release of ET-1 in critically ill patients.

Endothelin-1↗
PubMed2006

Role of endothelin in chronic renal failure--developments in renal involvement.

Endothelin (ET)-1 is a potent vasoconstrictor with profibrotic and proinflammatory effects. Increasing evidence suggests that ET-1 and its cognate receptors are involved in a variety of progressive renal disorders, including diabetes, hypertension and glomerulonephritis. Several laboratory studies have demonstrated elevated expression of ET-1, which colocalizes with glomerular and tubulointerstitial injury, in addition to enhanced urinary excretion. Moreover, ET-1 expression correlates with disease severity and renal function. With the availability of ET receptor antagonists, a pathogenetic role has been further corroborated in animal models, demonstrating both structural and functional improvement. Thus, antagonizing the ET system may be useful in major renal pathologies associated with glomerular and tubulointerstitial damage.

Endothelin-1↗